IST 004
Alternative Names: IST-004; IST-4Latest Information Update: 28 Aug 2023
At a glance
- Originator Istesso
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
- No development reported Psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Discontinued Cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Psoriasis in United Kingdom
- 28 Aug 2023 No recent reports of development identified for research development in Rheumatoid-arthritis in United Kingdom
- 28 Aug 2023 No recent reports of development identified for research development in Ulcerative-colitis in United Kingdom